<?xml version='1.0' encoding='utf-8'?>
<document id="26589238"><sentence text="Combination therapy of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: rationale and evidences."><entity charOffset="23-37" id="DDI-PubMed.26589238.s1.e0" text="sodium-glucose" /></sentence><sentence text="No single antidiabetic agent can correct all the pathophysiologic defects manifested in type 2 diabetes mellitus (T2DM) and, therefore, multiple agents are often required to achieve optimal glycemic control" /><sentence text=" Combination therapies, having different mechanisms of action, not only have the potential to complement their action, but may possess the properties to counter the undesired compensatory response" /><sentence text=" Recent finding suggests that sodium-glucose co-transporter-2 inhibitors (SGLT2i) increase endogenous glucose production (EGP) from liver, due to the increase in glucagon which may offset its glucose-lowering potential"><entity charOffset="30-44" id="DDI-PubMed.26589238.s4.e0" text="sodium-glucose" /><entity charOffset="102-109" id="DDI-PubMed.26589238.s4.e1" text="glucose" /><entity charOffset="192-199" id="DDI-PubMed.26589238.s4.e2" text="glucose" /><pair ddi="false" e1="DDI-PubMed.26589238.s4.e0" e2="DDI-PubMed.26589238.s4.e0" /><pair ddi="false" e1="DDI-PubMed.26589238.s4.e0" e2="DDI-PubMed.26589238.s4.e1" /><pair ddi="false" e1="DDI-PubMed.26589238.s4.e0" e2="DDI-PubMed.26589238.s4.e2" /><pair ddi="false" e1="DDI-PubMed.26589238.s4.e1" e2="DDI-PubMed.26589238.s4.e1" /><pair ddi="false" e1="DDI-PubMed.26589238.s4.e1" e2="DDI-PubMed.26589238.s4.e2" /></sentence><sentence text=" In contrast, dipeptidyl peptidase-4 inhibitors (DPP4i) decrease glucagon and EGP" /><sentence text=" Especially in the light of this finding, combination therapies with SGLT2i and DPP4i are particularly appealing, and are expected to produce an additive effect" /><sentence text=" Indeed, studies find no drug-drug interaction between SGLT2i and DPP4i" /><sentence text=" Moreover, significant reduction in glycated hemoglobin has also been observed" /><sentence text=" This article aims to review the efficacy and safety of combination therapy of SGLT2i and DPP4i in T2DM" /><sentence text=" " /></document>